Impact of the COVID-19 Pandemic on Cancer Clinical Trials

Judy C. Boughey*, Rebecca A. Snyder, Olga Kantor, Linda Zheng, Akhil Chawla, Toan T. Nguyen, Shauna L. Hillman, Olwen M. Hahn, Sumithra J. Mandrekar, Christina L. Roland

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

The COVID-19 pandemic has had widespread impact on healthcare, resulting in modifications to how we perform cancer research, including clinical trials for cancer. The impact of some healthcare workers and study coordinators working remotely and patients minimizing visits to medical facilities impacted clinical trial participation. Clinical trial accrual dropped at the onset of the pandemic, with improvement over time. Adjustments were made to some trial protocols, allowing telephone or video-enabled consent. Certain study activities were permitted to be performed by local healthcare providers or at local laboratories to maximize patients’ ability to continue on study during these challenging times. We discuss the impact of COVID-19 on cancer clinical trials and changes at the local, cooperative group, and national level.

Original languageEnglish (US)
Pages (from-to)7311-7316
Number of pages6
JournalAnnals of surgical oncology
Volume28
Issue number12
DOIs
StatePublished - Nov 2021

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'Impact of the COVID-19 Pandemic on Cancer Clinical Trials'. Together they form a unique fingerprint.

Cite this